アデノシン5'-[二りん酸P2-[1-(1,4-ジヒドロ-3-カルバモイルピリジン-1-イル)-1,5-ジデオキシ-β-D-ribo-ペントフラノース-5-イル]]
Nadh
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
基本情報
- CAS
58-68-4- 標準SMILES
NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1- InChIKey
BOPGDPNILDQYTO-NNYOXOHSSA-N- 分子式
- C21H29N7O14P2
- 平均分子量
- 665.4 g/mol
- 単同位体質量
- 665.12477262
名称と識別子
- 優先名称
- Nadh
- IUPAC
- [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
- 現地名
- アデノシン5'-[二りん酸P2-[1-(1,4-ジヒドロ-3-カルバモイルピリジン-1-イル)-1,5-ジデオキシ-β-D-ribo-ペントフラノース-5-イル]]
- 英語名
- dihydrodiphosphopyridine nucleotide
- 分子式
- C21H29N7O14P2
- 分子量
- 665.44
名称と別名
NADHDPNHbeta-NADH58-68-41,4-Dihydronicotinamide adenine dinucleotideNADH2dihydronicotinamide adenine dinucleotideReduced nicotinamide adenine diphosphateReduced nicotinamide-adenine dinucleotideReduced Nicotinamide Adenine Dinucleotide[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate4J24DQ0916
名称をさらに表示
ジヒドロニコチンアミドアデニンジヌクレオチド還元ニコチンアミドアデニンジヌクレオチドジヒドロニコチンアミドモノヌクレオチド還元型ニコチンアミドアデニンジヌクレオチド還元型コデヒドロゲナーゼIアデノシン5'-[二りん酸P2-[1-(1,4-ジヒドロ-3-カルバモイルピリジン-1-イル)-1,5-ジデオキシ-β-D-ribo-ペントフラノース-5-イル]]ジヒドロコジマーゼ還元ニコチンアミドアデニン二りん酸ジヒドロコデヒドロゲナーゼI1-[5-O-(5'-アデニリルオキシホスホニル)-β-D-リボフラノシル]-1,4-ジヒドロニコチンアミド還元型補発酵素還元型コデヒドラーゼI
物性
構造計算による物性補完中
- XLogP
- -5.7
- 極性表面積
- 318 Ų
- 水素結合供与体数
- 8
- 水素結合受容体数
- 19
- 回転可能結合数
- 11
- 重原子数
- 44
- 形式電荷
- 0
- 複雑度
- 1,230
実験および物理化学的性質
LogP-5.1
Melting Point
140.0-142.0 °C
140.0 - 142.0 °C
Physical DescriptionSolid
物理化学的性質
- 沸点
- 1081.8 · 1081.8±75.0 °C(Predicted)
- 比重(密度)
- 2.18 · 2.18±0.1 g/cm3(Predicted)
- 溶解性
- Water (Slightly)
- 酸解離定数(Pka)
- 1.13 · 1.13±0.50(Predicted)
- 外見
- Solid
- 色
- White to Off-White
- 安定性
- Light Sensitive, Temperature Sensitive
- InChIKey
- BOPGDPNILDQYTO-NNYOXOHSSA-N
- EPAの化学物質情報
- 5 · Adenosine 5'-(trihydrogen diphosphate), P'.fwdarw.5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide (58-68-4)
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
危険有害性情報
Regulatory Information
Chemical: Adenosine 5â²-(trihydrogen diphosphate), Pâ².fwdarw.5â²-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide
Adenosine 5'-(trihydrogen diphosphate), P'â5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide, disodium salt: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationEvaluation - Chemicals that are unlikely to require further regulation to manage risks to environment
法規制情報
Regulatory Information
Chemical: Adenosine 5â²-(trihydrogen diphosphate), Pâ².fwdarw.5â²-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide
Adenosine 5'-(trihydrogen diphosphate), P'â5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide, disodium salt: Does not have an individual approval but may be used under an appropriate group standard
安全データ
- tsca
- TSCA listed
化学と産業
薬理情報
Pharmacodynamics
A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). The action of supplemental NADH is unclear. Oral NADH supplementation has been used to combat simple fatigue as well as such mysterious and energy-sapping disorders as chronic fatigue syndrome and fibromyalgia. Researchers are also studying the value of NADH supplements for improving mental function in people with Alzheimer's disease, and minimizing physical disability and relieving depression in people with Parkinson's disease. Some healthy individuals also take NADH supplements orally to improve concentration and memory capacity, as well as to increase athletic endurance. However, to date there have been no published studies to indicate that using NADH is in any way effective or safe for these purposes.
Mechanism of Action
NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.
Absorption, Distribution and ExcretionUnclear how much of an administered dose is absorbed.
Tissue LocationsBladder；Brain；Fibroblasts；Platelet；Skeletal Muscle
Cellular LocationsEndoplasmic reticulum；Mitochondria；Peroxisome
Metabolite Pathways
11-beta-hydroxylase deficiency (CYP11B1)；17-alpha-hydroxylase deficiency (CYP17)；17-Beta Hydroxysteroid Dehydrogenase III Deficiency；2-aminoadipic 2-oxoadipic aciduria；2-Hydroxyglutric Aciduria (D And L Form)；2-ketoglutarate dehydrogenase complex deficiency；2-Methyl-3-Hydroxybutryl CoA Dehydrogenase Deficiency；21-hydroxylase deficiency (CYP21)；27-Hydroxylase Deficiency；3-Beta-Hydroxysteroid Dehydrogenase Deficiency；Total 46220 pathways, visit the HMDB page for details
関連反応
141 件
化合物ノート
読み込み中…